SLV-308. Solvay.

Article Details

Citation

Wolf WA

SLV-308. Solvay.

Curr Opin Investig Drugs. 2003 Jul;4(7):878-82.

PubMed ID
14619412 [ View in PubMed
]
Abstract

Solvay is developing SLV-308 (SME-308), a partial dopamine D2 agonist and noradrenergic agonist with serotonin 5-HT1A agonist properties, for the potential oral treatment of Parkinson's disease (PD), panic and depression. By January 2001, SLV-308 had entered phase II trials for PD and phase I trials for anxiety and depression.

DrugBank Data that Cites this Article

Drugs